Shopping Cart 0
Cart Subtotal
USD 0

Otonomy Inc (OTIC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company's Otiprio is the US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses Otividex for the treatment of Meniere's disease (Phase 3); OTO-313 for the treatment of tinnitus (Phase 1/2); OTO-5XX for the treatment of cisplatin-induced hearing loss (Phase 2), OTO-413 for the treatment of synaptopathy hearing loss; and OTO-6XX for the treatment of severe hearing loss. Otonomy is also investigating a preclinical program on sensorineural hearing loss including age-related hearing loss. It employs its proprietary formulation technology that uses a thermosensitive gel and drug microparticles for enabling single dose treatment by a physician. Otonomy is headquartered in San Diego, California, the US.

Otonomy Inc (OTIC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Otonomy Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Otonomy Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Otonomy Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Otonomy Acquires Assets and Patent Rights From NeuroSystec 11

Venture Financing 12

Otonomy Raises USD 49 Million In Series D Venture Financing 12

Otonomy Raises USD 46 Million In Series C Venture Financing 14

Partnerships 16

Otonomy Enters into Co-Promotion Agreement with Mission Pharmacal 16

Licensing Agreements 17

Otonomy Enters into Licensing Agreement with Ipsen 17

Otonomy Enters into Licensing Agreement with Durect 18

Equity Offering 19

Otonomy Raises USD115 Million in Public Offering of Shares 19

Otonomy Raises USD86 Million in Public Offering of Shares 21

Otonomy Completes Underwriters Exercise of Over-Allotment Option of IPO for USD115 Million 23

Otonomy Inc-Key Competitors 25

Otonomy Inc-Key Employees 26

Otonomy Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Strategy And Business Planning 28

Nov 27, 2017: Otonomy Announces Plan to Focus Resources on Development Programs 28

Financial Announcements 29

Nov 05, 2018: Otonomy reports third quarter 2018 financial results and provides corporate update 29

Aug 08, 2018: Otonomy reports second quarter 2018 financial results and provides corporate update 31

May 09, 2018: Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update 33

Mar 08, 2018: Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 34

Nov 08, 2017: Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36

Aug 03, 2017: Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update 37

May 04, 2017: Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update 39

Mar 02, 2017: Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 41

Product News 43

07/18/2017: Otonomy Announces FDA Acceptance of OTIPRIO Supplemental New Drug Application Filing for Acute Otitis Externa 43

Clinical Trials 44

Nov 08, 2017: Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX in Patients with Meniere's Disease 44

Aug 30, 2017: Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX in Patients with Menieres Disease 45

Jun 22, 2017: Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO in Acute Otitis Media with Tympanostomy Tubes 46

Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere's Disease 47

May 12, 2017: Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting 48

Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss 49

Jan 05, 2017: Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO in Patients with Acute Otitis Externa 50

Other Significant Developments 51

Jan 09, 2018: Otonomy Provides Corporate and Product Pipeline Update 51

Sep 13, 2017: Otonomy Provides Business and Financial Update 53

Jan 09, 2017: Otonomy Provides Corporate and Product Pipeline Update 54

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Otonomy Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Otonomy Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Otonomy Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Otonomy Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Otonomy Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Otonomy Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Otonomy Acquires Assets and Patent Rights From NeuroSystec 11

Otonomy Raises USD 49 Million In Series D Venture Financing 12

Otonomy Raises USD 46 Million In Series C Venture Financing 14

Otonomy Enters into Co-Promotion Agreement with Mission Pharmacal 16

Otonomy Enters into Licensing Agreement with Ipsen 17

Otonomy Enters into Licensing Agreement with Durect 18

Otonomy Raises USD115 Million in Public Offering of Shares 19

Otonomy Raises USD86 Million in Public Offering of Shares 21

Otonomy Completes Underwriters Exercise of Over-Allotment Option of IPO for USD115 Million 23

Otonomy Inc, Key Competitors 25

Otonomy Inc, Key Employees 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Otonomy Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Summary

Otonomy Inc (Otonomy) develops and markets treatments for diseases and disorders of the ear. The company's Otiprio is the US FDA approved ciprofloxacin otic suspension indicated during tympanostomy tube placement surgery in pediatric patients. Its pipeline portfolio encompasses Otividex for the treatment of Meniere's disease (Phase 3); OTO-313 for the treatment of tinnitus (Phase 1/2); OTO-5XX for the treatment of cisplatin-induced hearing loss (Phase 2), OTO-413 for the treatment of synaptopathy hearing loss; and OTO-6XX for the treatment of severe hearing loss. Otonomy is also investigating a preclinical program on sensorineural hearing loss including age-related hearing loss. It employs its proprietary formulation technology that uses a thermosensitive gel and drug microparticles for enabling single dose treatment by a physician. Otonomy is headquartered in San Diego, California, the US.

Otonomy Inc (OTIC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Otonomy Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Otonomy Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Otonomy Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Otonomy Acquires Assets and Patent Rights From NeuroSystec 11

Venture Financing 12

Otonomy Raises USD 49 Million In Series D Venture Financing 12

Otonomy Raises USD 46 Million In Series C Venture Financing 14

Partnerships 16

Otonomy Enters into Co-Promotion Agreement with Mission Pharmacal 16

Licensing Agreements 17

Otonomy Enters into Licensing Agreement with Ipsen 17

Otonomy Enters into Licensing Agreement with Durect 18

Equity Offering 19

Otonomy Raises USD115 Million in Public Offering of Shares 19

Otonomy Raises USD86 Million in Public Offering of Shares 21

Otonomy Completes Underwriters Exercise of Over-Allotment Option of IPO for USD115 Million 23

Otonomy Inc-Key Competitors 25

Otonomy Inc-Key Employees 26

Otonomy Inc-Locations And Subsidiaries 27

Head Office 27

Recent Developments 28

Strategy And Business Planning 28

Nov 27, 2017: Otonomy Announces Plan to Focus Resources on Development Programs 28

Financial Announcements 29

Nov 05, 2018: Otonomy reports third quarter 2018 financial results and provides corporate update 29

Aug 08, 2018: Otonomy reports second quarter 2018 financial results and provides corporate update 31

May 09, 2018: Otonomy Reports First Quarter 2018 Financial Results and Provides Corporate Update 33

Mar 08, 2018: Otonomy Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 34

Nov 08, 2017: Otonomy Reports Third Quarter 2017 Financial Results and Provides Corporate Update 36

Aug 03, 2017: Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update 37

May 04, 2017: Otonomy Reports First Quarter 2017 Financial Results and Provides Corporate Update 39

Mar 02, 2017: Otonomy Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 41

Product News 43

07/18/2017: Otonomy Announces FDA Acceptance of OTIPRIO Supplemental New Drug Application Filing for Acute Otitis Externa 43

Clinical Trials 44

Nov 08, 2017: Otonomy Reports Positive Results from AVERTS-2 Phase 3 Trial of OTIVIDEX in Patients with Meniere's Disease 44

Aug 30, 2017: Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX in Patients with Menieres Disease 45

Jun 22, 2017: Otonomy Announces Successful End-of-Phase 2 Review by FDA for OTIPRIO in Acute Otitis Media with Tympanostomy Tubes 46

Jun 20, 2017: Otonomy to Host Key Opinion Leader Meeting for Investors on Meniere's Disease 47

May 12, 2017: Otonomy Announces OTIPRIO Data Presentation and Symposium at the American Society of Pediatric Otolaryngology Annual Meeting 48

Jan 19, 2017: Otonomy Initiates Patient Enrollment in Phase 2 Clinical Trial of OTO-104 as Protectant Against Cisplatin-Induced Hearing Loss 49

Jan 05, 2017: Otonomy Announces Positive Top-Line Results from Phase 3 Clinical Trial of OTIPRIO in Patients with Acute Otitis Externa 50

Other Significant Developments 51

Jan 09, 2018: Otonomy Provides Corporate and Product Pipeline Update 51

Sep 13, 2017: Otonomy Provides Business and Financial Update 53

Jan 09, 2017: Otonomy Provides Corporate and Product Pipeline Update 54

Appendix 56

Methodology 56

About GlobalData 56

Contact Us 56

Disclaimer 56


List Of Figure

List of Figures

Otonomy Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Otonomy Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Otonomy Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Otonomy Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Otonomy Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Otonomy Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Otonomy Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Otonomy Acquires Assets and Patent Rights From NeuroSystec 11

Otonomy Raises USD 49 Million In Series D Venture Financing 12

Otonomy Raises USD 46 Million In Series C Venture Financing 14

Otonomy Enters into Co-Promotion Agreement with Mission Pharmacal 16

Otonomy Enters into Licensing Agreement with Ipsen 17

Otonomy Enters into Licensing Agreement with Durect 18

Otonomy Raises USD115 Million in Public Offering of Shares 19

Otonomy Raises USD86 Million in Public Offering of Shares 21

Otonomy Completes Underwriters Exercise of Over-Allotment Option of IPO for USD115 Million 23

Otonomy Inc, Key Competitors 25

Otonomy Inc, Key Employees 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products

Otonomy Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

chat_bubbleLet's Chat